Return to Publications  |  Return to CINJ Home
Rutgers Cancer Institute of New Jersey's Cancer Connection, June 2015
Donate NowThe latest news on research, treatment, prevention and education from the
state's only National Cancer Institute-designated Comprehensive Cancer Center
Investigational Immunotherapy Treatment Shows Durable Response in Patients with Metastatic Melanoma



Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and professor of surgery and medicine at Rutgers Robert Wood Johnson Medical School, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore. The work, which examines the oncolytic virus talimogene laherparepvec and its ability to reduce the size of melanoma tumors injected with the treatment, appears in the latest edition of the Journal of Clinical Oncology.Learn more

Rutgers Cancer Institute of New Jersey Reports Advances with Pembrolizumab in Small Cell Lung Cancer



Rutgers Cancer Institute of New Jersey investigators in its Phase I - Developmental Therapeutics Program, along with other colleagues have demonstrated that the immunotherapy drug pembrolizumab is generally well tolerated in those with small cell lung cancer, one of the most difficult to treat forms of lung cancer when it is in advanced stages. Senior author of the work, Janice M. Mehnert, MD, an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, presented the data at the recent American Society of Clinical Oncology (ASCO) Annual Meeting.Learn more

87,000 Miles and Counting



Having contributed nearly $1.4 million over the past decade to research efforts in leukemia, lymphoma, and kidney cancer at Rutgers Cancer Institute of New Jersey, the Century for the Cure charity bike ride is gearing up for another successful year. Registration is now open for this year's September 20 event, which features 100-mile, 62-mile and 40-mile treks. Organizers are hoping to raise $300,000 this year.Learn more

Rutgers Cancer Institute is One of Seven Worldwide Sites to Offer Debulking Prostatectomy Clinical Trial



Rutgers Cancer Institute of New Jersey is one of seven international sites to offer a clinical trial investigating the benefits of a debulking prostatectomy in men newly diagnosed with prostate cancer that has metastasized. The goal is to improve the effectiveness of other treatments, such as chemotherapy or radiation given after surgery. Cancer Institute Urologic Oncology Chief Isaac Yi Kim, MD, PhD, who is also an associate professor of surgery and chief of urology at Rutgers Robert Wood Johnson Medical School, is leading the trial locally.Learn more

Celebrating Dedicated Professionals During the Recent Oncology Nursing Month



Along with caring for and administering treatments to cancer patients, oncology nurses at Rutgers Cancer Institute of New Jersey engage in cancer research, mentor colleagues and develop education materials and programs for both patients and fellow nurses. Cancer Institute nurses Magdalena Samborski, RN, BSN, OCN and Susan Pillet, MSN, RN, CPNP, CPON were selected by their peers to receive Oncology Nursing Excellence Awards during a special center-wide ceremony during the recent Oncology Nursing Month that honored all Cancer Institute nurses for their passion and dedication to the field.Learn more

            Rutgers Cancer Institute of New Jersey                                          NCI logo 

Office of Communications         ·        ·        732-235-9871

                        Like us on Facebook                     Join the CINJ Mailing List